Disclosure of Interests in Mural Oncology by The Vanguard Group

The Vanguard Group, Inc., as stated in its recent Form 8.3 release, disclosed its interest in Mural Oncology plc under the oversight of the Irish Takeover Panel. The document, dated May 28, 2025, outlines specifics regarding its involvement and holdings in the company. According to the disclosure, The Vanguard Group holds 772,849 ordinary shares of $0.01, making up 4.48% of Mural Oncology's relevant securities.

The document further indicates a recent transaction by The Vanguard Group involving the sale of 18 ordinary shares at $2.63 each. There are no cash-settled or stock-settled derivative positions reported at this time. Additionally, there are no indemnities or arrangements relating to the securities that could influence dealings.

No supplemental Form 8 accompanies this disclosure, signifying the details provided are comprehensive for this transaction. The information reflects The Vanguard Group's engagement with Mural Oncology, emphasizing their significant stake in the biotech entity.